

CIN: L27100TG1989PLC010122

ZENOTECH LABORATORIES LIMITED

Registered Office & Factory:

Survey No.250 -252

Turkapally Village, Genome Valley Road,
Shamirpet Mandal

Medchal-Malkajgiri Dist.,

Turkapallyadaram,

Hyderabad - 500 101 Telangana, India

Tel: +91 90320 44584/ 585

Email: info@zenotech.co.in

www.zenotechlab.com

Date: October 28, 2026

BSE Limited

Market Operations Dept.,
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Scrip Code: 532039

Zenotech Laboratories Limited - Outcome of the Board Meeting held today i.e., October 28, 2026

Further to the communication dated October 17, 2026, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), this is to inform that the Meeting of the Board of Directors of the Company ("Board") was held today, i.e., October 28, 2026, which commenced at 12:00 P.M. IST/Noon and ended at 2:10 P.M. IST.

The Board has, *inter-alia*, approved the Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2026, as approved pursuant to Regulation 33 of the Listing Regulations, along with the Limited Review Report of the Statutory Auditors, are annexed herewith.

For Zenotech Laboratories Limited

**ABDUL GAFOOR
MOHAMMAD**

Digitally signed by ABDUL GAFOOR MOHAMMAD
DN: c=IN, o=Personal, title=ES60,
pseudoym=r8bz7h514mrvag8d8fypocje90z,
2.5.4.20=cce0597ab7438933adbedabbaad81b26kr7f7f
5c01f1914a4f9f14d3b78f8e, postalCode=500089,
st=Andhra Pradesh,
serialNumber=2bd0f97474015a367f30a376d5d0d0ff4cb
01774828a4d386fd30165c34986005, cn=ABDUL
GAFOOR MOHAMMAD
Date: 2026.10.28 14:26:01 +05'30'

(Abdul Gafoor Mohammad)

Company Secretary & Compliance Officer

ICSI Membership No.: A22331

Encl: as above

Independent Auditor's Review Report On Quarterly and Year to Date Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

**Review Report To
The Board of Directors
Zenotech Laboratories Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Zenotech Laboratories Limited (the "Company") for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For G S K A & Co.
Chartered Accountants
ICAI Firm Registration Number: 147093W


per **Ganesh Gaikwad**
Partner
Membership Number: 136512
UDIN: 26136512PZPMGO9962
Place of signature: Pune
Date: October 28, 2026



ZENOTECH LABORATORIES LIMITED

CIN: L27100TG1989PLC010122

Survey No.250-252, Turkapally Village, Genome Valley Road, Shameerpet Mandal, Medchal-Malkajgiri District, Hyderabad - 500101, Telangna

Phone: +91 90320 44584/585 Website: www.zenotechlab.com

Standalone Balance Sheet as at September 30, 2026

Rs in Lakhs

Particulars	As at 30 September 2026	As at 31 March 2026
	(Unaudited)	(Audited)
ASSETS		
(1) Non current assets		
(a) Property, plant and equipment	6,549.06	6,228.98
(b) Capital work-in-progress	269.54	360.33
(c) Financial assets		
(i) Investments	-	-
(ii) Others	134.77	125.82
(d) Deferred tax assets (net)	16.14	-
(e) Income tax assets	379.87	283.20
(f) Other non-current assets	38.56	13.09
Total non - current assets	7,387.94	7,011.42
(2) Current assets		
(a) Inventories	155.40	-
(b) Financial assets		
(i) Trade receivables	187.07	877.68
(ii) Cash and cash equivalents	2,854.12	3,028.93
(iii) Bank balances other than above	13.49	13.49
(iv) Other financial asset	247.65	143.04
(c) Other current assets	141.89	40.79
Total current assets	3,599.62	4,103.93
TOTAL ASSETS	10,987.56	11,115.35
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	6,103.06	6,103.06
(b) Other equity	3,109.29	3,409.05
Total equity	9,212.35	9,512.11
LIABILITIES		
(1) Non-current Liabilities		
(a) Financial liabilities		
(i) Other financial liabilities	101.97	97.25
(b) Other non current liabilities	-	1.88
(c) Provisions	215.33	215.33
(d) Deferred tax liabilities (net)	-	83.14
Total non - current liabilities	317.30	397.60
(2) Current Liabilities		
(a) Financial liabilities		
(i) Trade payables		
(a) Total outstanding dues of micro and small enterprises	129.82	51.81
(b) Total outstanding dues other than above	325.75	317.83
(ii) Other financial liabilities	350.68	309.35
(b) Other current liabilities	166.40	78.64
(c) Provisions	485.26	448.01
(d) Current tax liabilities (net)	-	-
Total current liabilities	1,457.91	1,205.64
TOTAL EQUITY AND LIABILITIES	10,987.56	11,115.35



ZENOTECH LABORATORIES LIMITED

CIN: L27100TG1989PLC010122

Survey No.250-252, Turkapally Village, Genome Valley Road, Shameerpet Mandal, Medchal-Malkajgiri District, Hyderabad - 500101, Telangna

Phone: +91 90320 44584/585 Website: www.zenotechlab.com

Statement of Unaudited Standalone Financial Results for the Quarter and Half Year ended 30 September 2026

Sl. No.	Particulars	(Rs in lakhs, except earnings per share)					
		Quarter ended			Half Year ended		Year ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	613.15	959.64	1,023.19	1,572.79	1,887.10	3,956.20
II	Other operating income	101.59	101.58	100.43	203.17	200.84	405.16
III	Other Income	42.41	43.57	70.02	85.98	128.86	230.90
IV	Total Income (I+II+III)	757.15	1,104.79	1,193.64	1,861.94	2,216.80	4,592.26
V	Expenses						
a)	Cost of materials consumed	-	-	-	-	-	-
b)	Purchase of Stock-in-Trade	-	-	-	-	-	-
c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
d)	Employee benefit expenses	469.30	491.63	380.44	960.93	733.99	1,552.79
e)	Depreciation and amortization expense	181.53	190.23	178.20	371.76	355.57	711.34
f)	Other expenses	448.41	483.00	514.15	931.41	878.70	1,889.72
	Total expenses	1,099.24	1,164.86	1,072.79	2,264.10	1,968.26	4,153.85
VI	Profit/(Loss) before exceptional items and tax (IV-V)	(342.09)	(60.07)	120.85	(402.16)	248.54	438.41
VII	Exceptional items (Refer Note - 6 & 9)	-	-	4.97	-	4.97	(19.51)
VIII	Profit/(Loss) before tax (VI-VII)	(342.09)	(60.07)	125.82	(402.16)	253.51	418.90
IX	Tax expense						
a)	Current tax	-	-	(22.21)	-	-	-
b)	Prior period tax	-	-	(190.49)	-	(190.49)	48.93
c)	Deferred tax	(84.76)	(14.52)	422.17	(99.28)	428.69	477.18
	Total tax expense (IX)	(84.76)	(14.52)	209.47	(99.28)	238.20	526.11
X	Profit/(Loss) for the period (VIII-IX)	(257.33)	(45.55)	(83.65)	(302.88)	15.30	(107.21)
XI	Other comprehensive Income						
a)	Items that will not be reclassified to profit or loss						
Re - measurement of the defined benefit obligations		1.56	1.56	(0.59)	3.12	(1.19)	6.24
Less: Income tax		(0.40)	(0.39)	0.13	(0.79)	0.30	(1.57)
b)	Items that will be reclassified to profit or loss	-	-	-	-	-	-
Less: Income tax		-	-	-	-	-	-
	Total Other comprehensive income (a+b)	1.16	1.17	(0.46)	2.33	(0.89)	4.67
XII	Total comprehensive income for the period (X+/-XI)	(256.17)	(44.38)	(84.12)	(300.55)	14.41	(102.54)
XIII	Paid-up equity share capital (Face value of ₹ 10/- per share)	6,103.06	6,103.06	6,103.06	6,103.06	6,103.06	6,103.06
XIV	Reserves i.e Other equity						3,409.05
XV	Earnings/ (loss) per share (of ₹ 10/- each) (not annualised)						
a)	Basic	(0.42)	(0.07)	(0.14)	(0.50)	0.03	(0.18)
b)	Diluted	(0.42)	(0.07)	(0.14)	(0.50)	0.03	(0.18)

See accompanying notes to the financial results



ZENOTECH LABORATORIES LIMITED CIN: L27100TG1989PLC010122 Survey No.250-252, Turkapally Village, Genome Valley Road, Shameerpet Mandal, Medchal-Malkajgiri District, Hyderabad - 500101, Telangna Phone:+91 90320 44584/585 www.zenotechlab.com		
Standalone Cash flow statement for the Period ended September 30, 2026		Rs in Lakhs
	For Half year ended 30 September 2026	For Half year ended 30 September 2025
	(Unaudited)	(Unaudited)
A. Cash flows from operating activities		
Profit/(loss) before taxation	(402.16)	253.51
Adjustments for:		
Depreciation and amortisation	371.76	355.57
Amounts written back	-	(10.36)
Notional interest expense on security deposits	4.72	-
Notional income on advance rent	(3.79)	-
Unrealised foreign exchange loss, net	-	-
Interest income	(81.54)	(94.41)
Operating cash flows before working capital changes	(111.02)	504.31
Changes in Working Capital:		
(Increase)/ decrease in trade receivables	690.61	393.92
(Increase)/ decrease in inventories	(155.40)	-
(Decrease)/ increase in trade payables	85.93	(42.47)
(Increase)/ decrease in other financial assets	(103.19)	(65.47)
(Increase)/ decrease in current non financial assets	-	-
(Increase)/ decrease in non-current financial assets	(8.95)	10.00
(Increase)/ decrease in non-current assets	0.15	2.31
(Increase)/ decrease in other current assets	(101.10)	(37.61)
(Decrease)/ increase in provisions	40.37	25.59
(Decrease)/ increase in other financial liabilities	7.96	4.92
(Decrease)/ increase in other current liabilities	89.67	43.99
Cash used in operations	435.03	839.49
Income taxes paid/ TDS (net)	(96.67)	(6.59)
Net cash used in operating activities (A)	338.36	832.89
B.Cash flows from investing activities		
Payment for Purchase of property plant equipment (Including Capital advance & Work in Progress)	(593.29)	(423.83)
(Increase)/Decrease in other bank balances	-	-
Interest income received	80.12	94.41
Net cash provided by/ (used in) investing activities	(513.17)	(329.42)
C. Cash flows from financing activities		
Repayment of borrowings	-	-
Interest paid	-	-
Net cash provided by financing activities (C)	-	-
Net increase/ (decrease) in cash and cash equivalents during the year(A+B+C)	(174.81)	503.47
Cash and cash equivalents at the beginning of the year	3,028.93	2,657.51
Add/(less) exchange (loss)/gain on cash and cash equivalents	-	-
Cash and cash equivalents at the end of the year	2,854.12	3,160.98
Cash and cash equivalents include		
Balances with banks in current accounts	353.65	160.59
Deposits with original maturity of less than 3 months	2,500.00	3,000.00
Cash on hand	0.47	0.39
	2,854.12	3,160.98



Notes:

1. The Statement of unaudited financial results for quarter and half year ended September 30, 2026, is drawn up in accordance with the Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, which was reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on October 28, 2026. These results have been subjected to limited review by statutory auditors who have expressed an unmodified review conclusion.
2. The above results have been prepared in accordance with the recognition and measurement requirements of Indian Accounting Standards ("Ind AS") notified under Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
3. Majority of the matters relating to several financial and non-financial irregularities pertaining to period prior to November 12, 2011, were abated/settled. Accordingly, based on the steps taken by the Company and evidence available so far, the Company believes that the financial impact if any, with respect to those legacy matters, on the results of the Company is not material.
4. The Company's overseas subsidiaries namely Zenotech Farmaceutica Do Brasil Ltda (Zenotech-Brazil) and Zenotech Inc (Zenotech-USA) were defunct and reported as cancelled/revoked respectively based on the Registration Cancellation certificate dated 8th June 2022 and Long Form Standing certificate dated 15th June 2022 respectively, received from the concerned authorities.

Winding up order for Zenotech Laboratories Nigeria Limited has been received during FY: 2019-20. However, related filings with RBI are pending.

Accordingly, the Company is of the view that it does not have subsidiaries, joint ventures and associates within the definition of Ind AS 110 and hence consolidated financial statements/Results are no longer applicable.

5. Other operating income relates to rentals for the Biotech facility and equipment leased to Sun Pharmaceutical Industries Limited for R&D activities.
6. The Company has only one reportable segment, i.e. Pharmaceuticals.
7. The figures for the quarter ended 31st March, 2026 is the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year
8. Figures for previous period/ year have been regrouped to conform to the current period presentation.

By Order of the Board



Chairman of the Board meeting
DIN-01219312

Place: New Delhi
Date: October 28, 2026